ASPEN PHAR.UN.ADR /1 O.N. Market Cap ($2.95 Billion)
Market Cap & Net Worth: ASPEN PHAR.UN.ADR /1 O.N. (LDZU)
ASPEN PHAR.UN.ADR /1 O.N. market cap. ASPEN PHAR.UN.ADR /1 O.N. (F:LDZU) has a market capitalization of $2.95 Billion (€2.52 Billion) as of November 1, 2026. Listed on the F stock exchange, this Germany-based company holds position #4790 globally and #814 in its home market, demonstrating a 0.73% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ASPEN PHAR.UN.ADR /1 O.N.'s stock price €6.90 by its total outstanding shares 444022553 (444.02 Million). Also see ASPEN PHAR.UN.ADR /1 O.N. cash flow conversion for how efficiently the company converts equity into cash flow.
ASPEN PHAR.UN.ADR /1 O.N. Market Cap History (2019–2026)
ASPEN PHAR.UN.ADR /1 O.N. market cap history from 2019 to 2026. Data shows change from $3.66 Billion to $4.44 Billion (-0.34% CAGR). Check today's stock price for ASPEN PHAR.UN.ADR /1 O.N. for real-time trading data and today's change.
ASPEN PHAR.UN.ADR /1 O.N. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ASPEN PHAR.UN.ADR /1 O.N.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore LDZU year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.07x
ASPEN PHAR.UN.ADR /1 O.N.'s market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $3.55 Billion | $38.61 Billion | $6.49 Billion | 0.09x | 0.55x |
| 2023 | $4.72 Billion | $40.71 Billion | $5.23 Billion | 0.12x | 0.90x |
| 2024 | $4.44 Billion | $44.71 Billion | $4.40 Billion | 0.10x | 1.01x |
| 2025 | $3.04 Billion | $43.36 Billion | -$1.08 Billion | 0.07x | N/A |
Competitor Companies of LDZU by Market Capitalization
Companies near ASPEN PHAR.UN.ADR /1 O.N. in the global market cap rankings as of November 1, 2026. Also see LDZU total assets for a full breakdown of the balance sheet.
Key companies related to ASPEN PHAR.UN.ADR /1 O.N. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of ASPEN PHAR.UN.ADR /1 O.N. (2019–2026)
Market capitalization of ASPEN PHAR.UN.ADR /1 O.N. from 2019 to today. Between 2019 and today, ASPEN PHAR.UN.ADR /1 O.N.'s market cap moved from $3.66 Billion to $ 4.44 Billion, with a yearly change of -0.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €4.44 Billion | +46.15% |
| 2025 | €3.04 Billion | -31.58% |
| 2024 | €4.44 Billion | -6.02% |
| 2023 | €4.72 Billion | +33.05% |
| 2022 | €3.55 Billion | -38.94% |
| 2021 | €5.81 Billion | +82.85% |
| 2020 | €3.18 Billion | -13.12% |
| 2019 | €3.66 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of ASPEN PHAR.UN.ADR /1 O.N. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.95 Billion USD |
| MoneyControl | $2.95 Billion USD |
| MarketWatch | $2.95 Billion USD |
| marketcap.company | $2.95 Billion USD |
| Reuters | $2.95 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ASPEN PHAR.UN.ADR /1 O.N.
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic ag… Read more